Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach

PURPOSE: Multiple myeloma (MM) is a malignancy of plasma cells, with a median survival of 6 years. Despite recent therapeutic advancements, relapse remains mostly inevitable, and the disease is fatal in the majority of patients. A major challenge in the treatment of patients with relapsed MM is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Laganà, Alessandro, Beno, Itai, Melnekoff, David, Leshchenko, Violetta, Madduri, Deepu, Ramdas, Dennis, Sanchez, Larysa, Niglio, Scot, Perumal, Deepak, Kidd, Brian A., Miotto, Riccardo, Houldsworth, Jane, Shaknovich, Rita, Chari, Ajai, Cho, Hearn Jay, Barlogie, Bart, Jagannath, Sundar, Dudley, Joel T., Parekh, Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2018
Materias:
Original Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350920/
https://www.ncbi.nlm.nih.gov/pubmed/30706044
http://dx.doi.org/10.1200/PO.18.00019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350920/
https://www.ncbi.nlm.nih.gov/pubmed/30706044
http://dx.doi.org/10.1200/PO.18.00019

Ejemplares similares